Literature DB >> 30949687

A sequential interferon gamma directed chemotactic cellular immune response determines survival and cardiac function post-myocardial infarction.

Stefanie Finger1,2,3, Maike Knorr1,2, Michael Molitor1,2,3, Rebecca Schüler1,2,4, Venkata Garlapati2,3, Ari Waisman4, Moritz Brandt1,2, Thomas Münzel1,2,3, Tobias Bopp5, Sabine Kossmann1,2,6, Susanne Karbach1,2,3, Philip Wenzel1,2,3.   

Abstract

AIMS: Myelomonocytic cells are critical in injury and healing post-myocardial infarction (MI). Mechanisms of regulation, however, are incompletely understood. The aim of the study was to elucidate the role of interferon gamma (IFN-γ) in the orchestrated inflammatory response in a murine model of MI. METHODS AND
RESULTS: MI was induced in 8- to 12-week-old male mice (C57BL/6 background) by permanent ligation of the left anterior descending (LAD) coronary artery. Lysozyme M (LysM)+ cell-depleted LysMiDTR transgenic mice displayed a reduced influx of CD45.2+/CD3-/CD11b+/Gr-1high neutrophils into infarcted myocardium 1 day post-MI compared with infarcted controls, paralleled by decreased cardiac mRNA levels of IFN-γ and tumour necrosis factor alpha (TNF-α). Mortality after MI was significantly increased in LysM+ cell-depleted mice within 28 days post-MI. To more specifically address the role of neutrophils, we depleted C57BL/6 mice with a monoclonal anti-Gr-1 antibody and found increased mortality, deteriorated cardiac function as well as decreased cardiac IFN-γ mRNA expression early after MI. Ccl2, Cxcl1, Cx3cl1, and Il12b mRNA were reduced 3 days after MI, as was the amount of CD11b+/Ly-6G-/Ly-6Chigh inflammatory monocytes. LAD-ligated Cramp-/- mice lacking cathelicidin important in neutrophil-dependent monocyte chemotaxis as well as IFNγ-/- and TNFα-/- mice phenocopied Gr-1+ cell-depleted mice, supporting a regulatory role of IFN-γ impacting on both the sequence of inflammatory cell invasion and cardiac outcome early after MI. The use of conditional IFN-γ receptor deficient mice indicated a direct effect of IFN-γ on LysM+ cells in cardiac injury post-MI. Using IFN-γ reporter mice and flow cytometry, we identified cardiac lymphoid cells (CD4+ and CD8+ T cells and natural killer cells) as primary source of this cytokine in the cardiac inflammatory response post-MI.
CONCLUSION: IFN-γ directs a sequential chemotactic cellular immune response and determines survival and cardiac function post-MI. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Interferon gamma; Myelomonocytic cells; Myocardial infarction

Mesh:

Substances:

Year:  2019        PMID: 30949687     DOI: 10.1093/cvr/cvz092

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  4 in total

1.  Interferon-γ regulates cardiac myeloid cells in myocardial infarction.

Authors:  Friedrich F Hoyer; Matthias Nahrendorf
Journal:  Cardiovasc Res       Date:  2019-11-01       Impact factor: 10.787

2.  Exosomes Derived From Epigallocatechin Gallate-Treated Cardiomyocytes Attenuated Acute Myocardial Infarction by Modulating MicroRNA-30a.

Authors:  Chan Zhang; Xiaowen Gan; Ronggan Liang; Jie Jian
Journal:  Front Pharmacol       Date:  2020-02-26       Impact factor: 5.810

3.  Aging impairs human bone marrow function and cardiac repair following myocardial infarction in a humanized chimeric mouse.

Authors:  Tina B Marvasti; Faisal J Alibhai; Lukasz Wlodarek; Anne Fu; Shu-Hong Li; Jun Wu; Richard D Weisel; Robert J Cusimano; Maral Ouzounian; Terrence Yau; Ren-Ke Li
Journal:  Aging Cell       Date:  2021-10-06       Impact factor: 9.304

4.  ACE Inhibition Modulates Myeloid Hematopoiesis after Acute Myocardial Infarction and Reduces Cardiac and Vascular Inflammation in Ischemic Heart Failure.

Authors:  Wolf-Stephan Rudi; Michael Molitor; Venkata Garlapati; Stefanie Finger; Johannes Wild; Thomas Münzel; Susanne H Karbach; Philip Wenzel
Journal:  Antioxidants (Basel)       Date:  2021-03-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.